Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Pituitary-Tumor Endocrinopathies Pituitary adenomas account for about 15% of intracranial
tumors. Clinical manifestations of disease reflect the oversecretion of the involved hormone …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has
caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare …

Abstract Context Approximately 10% to 20% of prolactinomas are resistant to dopamine
agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior …

Context There are growing reports of dopamine agonist (DA)-induced impulse control
disorders (ICDs) in hyperprolactinemic patients. However, the magnitude of this risk and …

Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of
normal range, is a common finding in clinical practice and prolactinomas are the main …

Context Although consensus guidelines recommend dopamine agonists (DAs) as the first-
line approach in prolactinomas, some patients may opt instead for upfront surgery, with the …

Background: Dopamine agonists (DA) are the first line therapy for prolactinoma and
symptomatic hyperprolactinemia; use as an adjuvant treatment for acromegaly and …

Dopamine inhibits prolactin secretion from lactotroph cells by modulation of prolactin gene
expression, cellular proliferation, and neoplastic cell apoptosis. 1 Among the 5 types of …